Founded in 2021, NEX-I Co., Ltd. is a South Korean biotechnology company specializing in the development of next-generation immunotherapeutics aimed at enhancing the efficacy of cancer treatments. The company's platform designs assessment tools to evaluate the target efficacy of cancer immunotherapy, striving to improve the quality of life for patients and their families by controlling tumor growth through the activation of both dendritic cells and cytolytic T cells.

ONCOKINE Platform: A group of protein derivatives present in the tumor microenvironment, designed to control tumor growth by activating both dendritic cells and cytolytic T cells, thereby enhancing the body's immune response against cancer.

Private

Biotech